Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Relapsed/Refractory ALL Paradigm Rapidly Evolving With Novel Agents

Jessica Hergert
Published: Thursday, Jan 09, 2020

Jonathan E. Brammer, MD, an assistant professor in internal medicine at The Ohio State University Comprehensive Cancer Center-James

Jonathan E. Brammer, MD

The introduction of multiple agents including CAR T-cell therapy, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates has revolutionized the treatment landscape of relapsed/refractory acute lymphoblastic leukemia (ALL), said Jonathan E. Brammer, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication